PIKA COVID-19 Vaccine (YS-SC2-010) / YS Biopharma - LARVOL DELTA

Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study. (PubMed, Clin Exp Vaccine Res) - P2/3 | "The PIKA COVID-19 vaccine, when administered as a booster dose, showed promising short- and long-term immunogenicity with no emergent safety issues identified. The booster dose of the PIKA COVID-19 vaccine elicited a robust immune response against various SARS-CoV-2 variants and provided some seroprotection for up to 360 days (ClinicalTrials.gov registration number: NCT05463419)."

Clinical • Journal • P2 data • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases

A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose. (clinicaltrials.gov) - P2/3 | N=5860 | Completed | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose. (clinicaltrials.gov) - P2/3 | N=5860 | Active, not recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | Recruiting ➔ Active, not recruiting | N=9300 ➔ 5860 | Trial completion date: Dec 2023 ➔ Apr 2024

Enrollment change • Enrollment closed • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose. (clinicaltrials.gov) - P2/3 | N=9300 | Recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals (clinicaltrials.gov) - P1 | N=135 | Completed | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose. (clinicaltrials.gov) - P2/3 | N=9300 | Not yet recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd.

New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals (clinicaltrials.gov) - P1 | N=135 | Active, not recruiting | Sponsor: Yisheng Biopharma (Singapore) Pte. Ltd.

New P1 trial • Infectious Disease • Novel Coronavirus Disease